GlassScriptPhysician profile
Thomas W Coleman
NPI 1245348218
$7,042.42
in general payments reported to CMS, 2019-2025
49 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $465 · 2021: $805 · 2022: $1,258 · 2023: $987 · 2024: $1,096 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,609.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $966.84 | 2019-2025 | Erleada, Akeega, Balversa |
| Coloplast Corp | $522.68 | 2019-2025 | Titan, Speedicath |
| Neotract INC. | $515.26 | 2019-2020 | |
| Teleflex LLC | $431.15 | 2021-2023 | Urolift |
| Sumitomo Pharma America, INC. | $393.26 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $358.38 | 2019-2023 | Xtandi |
| Antares Pharma, INC. | $322.14 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Endo Pharmaceuticals INC. | $303.52 | 2020-2024 | Xiaflex, Aveed, Edex |
| Profound Medical Corp. | $286.47 | 2025 | Tulsa-Pro |
| Procept Biorobotics Corporation | $250.82 | 2024 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $224.52 | 2022-2025 | Provenge |
| Immunitybio, INC. | $224.19 | 2025 | |
| Pfizer INC. | $220.35 | 2019-2025 | |
| Urogen Pharma, INC. | $212.37 | 2021-2025 | |
| Boston Scientific Corporation | $184.82 | 2023-2025 | General - Erectile Dysfunction |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $179.04 | 2021-2024 | Prolaris, Myrisk |
| Myovant Sciences INC. | $128.83 | 2021-2022 | |
| Olympus America INC. | $115.50 | 2020-2023 | Itind System |
| Endo USA, INC. | $109.62 | 2024-2025 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $105.14 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Urovant Sciences INC | $90.89 | 2022 | |
| Allergan, INC. | $87.54 | 2020-2021 | |
| C. R. Bard, INC. & Subsidiaries | $75.57 | 2019-2025 | Magic3 Go Intermittent Urinary Catheter |
| Blue Earth Diagnostics | $66.13 | 2021-2022 | |
| Tolmar, INC. | $58.04 | 2023-2024 | |
| Tolmar Pharmaceuticals, INC. | $44.84 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $41.94 | 2024 | Adstiladrin |
| Clarus Therapeutics INC. | $40.02 | 2021 | |
| Mission Pharmacal Company | $39.35 | 2022-2024 | Uribel, Uribel Tabs |
| 180 Medical, INC. | $36.44 | 2024-2025 | Gentlecath Glide, Gentlecath |
| Baxter Healthcare | $35.80 | 2019-2021 | |
| Novo Nordisk INC | $34.38 | 2024-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $33.20 | 2024 | |
| Verity Pharmaceuticals INC. | $30.81 | 2025 | Tlando, Trelstar |
| Telix Pharmaceuticals | $30.46 | 2023-2024 | Illuccix |
| Axonics, INC. | $28.48 | 2022-2023 | Bulkamid |
| Photocure INC | $27.86 | 2022-2024 | Cysview |
| Astrazeneca Pharmaceuticals LP | $24.59 | 2020-2023 | Breztri |
| I/O Urology Corp. | $20.69 | 2025 | Carepath |
| Rochester Medical Corporation | $19.35 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.41 | 2025 | |
| Accord Healthcare, INC. | $16.44 | 2022 | |
| Progenics Pharmaceuticals, INC. | $15.87 | 2024 | |
| Lilly USA, LLC | $15.52 | 2024 | Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $15.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2021 | |
| Travere Therapeutics, INC. | $13.19 | 2020 | |
| Ethicon US, LLC | $12.24 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.